Hyperkalemia from preoperative non-steroidal anti-inflammatory drugs and angiotensin II receptor blockers in patients with nephropathy

Hyperkalemia from preoperative non-steroidal anti-inflammatory drugs and angiotensin II receptor blockers in patients with nephropathy

Bibliographic Details
Main Authors:	Ho Kyung Song, Yeon Jang, Jin Woo Nam, Ju-Hyun You
Format:	Article
Language:	English
Published:	Korean Society of Anesthesiologists 2011-12-01
Series:	Korean Journal of Anesthesiology
Online Access:	http://ekja.org/upload/pdf/kjae-61-533.pdf

Similar Items

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers
by: Seyed Ali Sadjadi, et al.
Published: (2009-07-01)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
by: Hyun Woo Lee, et al.
Published: (2021-03-01)

Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Contrast-Induced Nephropathy
by: Letian Zhou, et al.
Published: (2014-03-01)

Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison
by: Nicolás Roberto Robles, et al.
Published: (2009-12-01)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
by: Hyun Woong Lee
Published: (2014-12-01)

Association of serum sodium minus chloride level at initiation of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and hyperkalemia in patients with CKD: a case control study
by: Haruki Mae, et al.
Published: (2024-04-01)

Nephroprotective effect of vitamin E added to angiotensin receptor blocker in patients with diabetic nephropathy
by: Abdulrazzaq Alkaaby, et al.
Published: (2021-12-01)

Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan
by: Masanori Abe, et al.
Published: (2015-03-01)

Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy
by: Jin-Ying Fang, et al.
Published: (2020-03-01)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
by: Stephen eOrena, et al.
Published: (2013-10-01)

A Real-World Analysis of Post-Marketing Surveillance Data Assessing the Incidence of Hyperkalemia or Acute Kidney Injury in Patients on Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin-Receptor Blockers
by: Yining Wang, et al.
Published: (2023-04-01)

Angiotensin II type 1 receptor blockers favorably affect renal angiotensin II and MAS receptor expression in patients with diabetic nephropathy
by: Ye-Ping Ma, et al.
Published: (2020-05-01)

Meta-analysis of effect of renin–angiotensin–aldosterone system blockers on contrast-induced nephropathy
by: Weidong Wang, et al.
Published: (2020-05-01)

Angiotensin receptor blockers in heart failure
by: Jan Östergren, et al.
Published: (2003-09-01)

Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers
by: Neil Poulter, et al.
Published: (2006-06-01)

The effect of renin–angiotensin system blockade on renal protection in chronic kidney disease patients with hyperkalemia
by: Ju-Hyun Lee, et al.
Published: (2014-12-01)

Interaction of -blockers and angiotensin receptor blockers/ACE inhibitors in heart failure
by: Jay N Cohn
Published: (2003-09-01)

Effects of Spironolactone in Combination with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients with Proteinuria
by: Ha Yeon Kim, et al.
Published: (2014-12-01)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
by: John D Bisognano, et al.
Published: (2007-11-01)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
by: Graham J. Moore, et al.
Published: (2021-07-01)

Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study
by: Ju Hwan Kim, et al.
Published: (2020-12-01)

Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy
by: Dan-Dan Qiu, et al.
Published: (2018-01-01)

The use of angiotensin receptor blockers in dementia prevention
by: Jordana de Araujo Müller, et al.
Published: (2023-09-01)

Place of angiotensin receptor blockers in antihypertensive therapy
by: A I Martynov, et al.
Published: (2014-03-01)

Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Inflammatory Response and Viral Clearance in COVID-19 Patients
by: Linna Huang, et al.
Published: (2021-08-01)

Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials
by: Fan Shunan, et al.
Published: (2018-10-01)

Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
by: Jin Sun Choi, et al.
Published: (2023-11-01)

Retrospective analysis of Tripterygium wilfordii polyglycoside combined with angiotensin receptor blockers for the treatment of primary membranous nephropathy with sub-nephrotic proteinuria
by: Yuanyuan Guo, et al.
Published: (2021-01-01)

The Effect of an Angiotensin Receptor Blocker on Arterial Stiffness in Type 2 Diabetes Mellitus Patients with Hypertension
by: Ji Hyun Kim, et al.
Published: (2011-06-01)

The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man
by: Alessandra Del Fiorentino, et al.
Published: (2009-02-01)

A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention
by: Ji-Guang Wang
Published: (2009-07-01)

Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria
by: Feng-Yi Hsu, et al.
Published: (2017-06-01)

Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case Series
by: Su Jin Lee, et al.
Published: (2021-05-01)

Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers
by: Georg Nickenig, et al.
Published: (2006-03-01)

Angiotensin Receptor Blockers: Cardiovascular Protection in the Metabolic Syndrome
by: Prakash C Deedwania, et al.
Published: (2006-03-01)

Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers
by: Georg Nickenig, et al.
Published: (2006-03-01)

Angiotensin Receptor Blockers: Cardiovascular Protection in the Metabolic Syndrome
by: Prakash C Deedwania, et al.
Published: (2006-03-01)

Clinical pharmacogenetics of angiotensin II receptor blockers in Iraq
by: Hany A Al-Hussaniy, et al.
Published: (2023-01-01)

Angiotensin II Receptor Blockers and Arrhythmias in Ventricular Hypertrophy
by: Guy Salama
Published: (2022-08-01)